Hospital
Medstar Southern Maryland Hospital Center INC
Medstar Southern Maryland Hospital Center INC was paid $18.35M by Medicaid between Jan 2018 and Nov 2024, across 111 billing codes. Its largest line is 41899, Unlisted procedure, dentoalveolar structures — 21% of everything it billed.
33Billing provider infoMEDSTAR SOUTHERN MARYLAND HOSPITAL CENTER INC
CLINTON, MD 20735
CLINTON, MD 20735
33aNPI1366790693assigned 08/16/2012
33bProvider typePsychiatric Hospital Unit
28Total paid$18.35M
24GClaims185,329
24DCodes billed111
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in Maryland
Rank by total paid#1 of 5
Median peer was paid$4.20M
This provider vs. median4.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 31,264 | $3.79M | |
| 2019 | 29,310 | $3.25M | |
| 2020 | 27,563 | $2.49M | |
| 2021 | 33,748 | $3.11M | |
| 2022 | 28,081 | $2.53M | |
| 2023 | 18,878 | $1.60M | |
| 2024incomplete | 16,485 | $1.59M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 41899 | Unlisted procedure, dentoalveolar structures | 21% | 726 | 636 | $3.77M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 10,829 | 9,587 | $3.24M |
| G0378 | Hospital observation service, per hour | 13% | 3,054 | 1,910 | $2.35M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 11,281 | 10,012 | $2.16M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 4,729 | 4,173 | $1.87M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 5.6% | 12,165 | 10,506 | $1.03M |
| 93976 | 2.3% | 649 | 572 | $424K | |
| 84484 | 1.5% | 8,481 | 6,682 | $281K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 20,214 | 14,681 | $266K |
| 80053 | Comprehensive metabolic panel | 1.3% | 11,580 | 9,328 | $231K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.2% | 1,357 | 1,251 | $216K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 2,006 | 1,738 | $209K |
99 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,479 | $180K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,685 | $157K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,903 | $154K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,268 | $145K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,851 | $125K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,023 | $122K |
| 81001 | <1% | 8,406 | $122K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,086 | $115K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,835 | $96K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 217 | $86K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,010 | $69K |
| 83690 | <1% | 4,790 | $61K | |
| 81025 | <1% | 2,614 | $58K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 217 | $57K |
| 87581 | <1% | 217 | $56K | |
| 83880 | <1% | 1,797 | $50K | |
| 84702 | <1% | 747 | $46K | |
| 84703 | <1% | 1,790 | $43K | |
| 87486 | <1% | 166 | $42K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 927 | $34K |
| 76801 | <1% | 80 | $31K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 587 | $30K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 299 | $30K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 301 | $28K |
| 83735 | <1% | 4,454 | $26K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,181 | $25K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 459 | $23K |
| 80320 | <1% | 568 | $23K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 73 | $22K |
| 85610 | <1% | 2,735 | $21K | |
| 82077 | <1% | 597 | $19K | |
| 87070 | <1% | 210 | $17K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 222 | $13K |
| 83605 | <1% | 445 | $13K | |
| 80076 | <1% | 804 | $13K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 58 | $11K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 178 | $10K |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,097 | $9K |
| 86901 | <1% | 1,060 | $8K | |
| 86900 | <1% | 1,062 | $8K | |
| 85379 | <1% | 186 | $7K | |
| 87428 | <1% | 87 | $6K | |
| 87077 | <1% | 292 | $6K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,711 | $5K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 91 | $5K |
| J3490 | Unclassified drugs | <1% | 694 | $5K |
| 73130 | <1% | 52 | $5K | |
| 87186 | <1% | 279 | $5K | |
| 82553 | <1% | 511 | $5K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,718 | $4K |
| 86850 | <1% | 366 | $4K | |
| 90715 | <1% | 61 | $3K | |
| 85730 | <1% | 512 | $3K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 14 | $2K |
| 73630 | <1% | 25 | $2K | |
| 87040 | <1% | 67 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,833 | $2K |
| 82550 | <1% | 516 | $2K | |
| 73562 | <1% | 18 | $2K | |
| 94760 | <1% | 378 | $2K | |
| 81003 | <1% | 344 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 597 | $2K |
| 73030 | <1% | 33 | $2K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 26 | $1K |
| 93971 | <1% | 12 | $1K | |
| 94762 | <1% | 61 | $1K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 611 | $1K |
| 80061 | Lipid panel | <1% | 105 | $1K |
| 82803 | <1% | 27 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 261 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,126 | $980.67 |
| 84100 | <1% | 404 | $851.71 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,080 | $816.65 |
| 94799 | <1% | 54 | $673.46 | |
| 73564 | <1% | 14 | $616.18 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 181 | $600.57 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 47 | $565.54 |
| 87210 | <1% | 27 | $549.26 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 26 | $509.92 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 124 | $466.78 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 315 | $442.60 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 198 | $424.46 |
| 94644 | <1% | 15 | $412.25 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 606 | $392.89 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 87 | $352.36 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 59 | $326.15 |
| 94664 | <1% | 53 | $310.04 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 254 | $301.06 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 90 | $290.20 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 14 | $276.96 |
| J2704 | Injection, propofol, 10 mg | <1% | 144 | $275.49 |
| 87088 | <1% | 16 | $220.96 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 30 | $154.81 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 741 | $136.09 |
| 85014 | <1% | 17 | $97.58 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 187 | $57.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 14 | $0.00 |
| 0270 | 0% | 293 | $0.00 | |
| C1769 | Guide wire | 0% | 56 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMEISEL, MICHAEL (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| ST Marys Hospital of ST Marys County INC | Leonardtown, MD | $3.54M |
| ST. Mary's Hospital of ST. Mary's County, INC. | Callaway, MD | $31K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.